Elanco Animal Health Incorporated Operating Cash Flow
Elanco Animal Health Incorporated (ELAN) reported Operating Cash Flow of $290.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- Elanco Animal Health Incorporated net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $277.00M, a 16.88% increase year-over-year.
- Elanco Animal Health Incorporated net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $13.00M.
- Elanco Animal Health Incorporated net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $108.00M, a 38.98% decline year-over-year.
- Elanco Animal Health Incorporated net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $219.00M, a 35.19% increase year-over-year.
- Elanco Animal Health Incorporated net cash provided by (used in) operating activities for fiscal 2025 was $560.00M, a 3.51% increase from fiscal 2024.
- Elanco Animal Health Incorporated net cash provided by (used in) operating activities for fiscal 2024 was $541.00M, a 99.63% increase from fiscal 2023.
- Elanco Animal Health Incorporated net cash provided by (used in) operating activities for fiscal 2023 was $271.00M, a 40.04% decline from fiscal 2022.
- Elanco Animal Health Incorporated net cash provided by (used in) operating activities for fiscal 2022 was $452.00M, a 6.42% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $277.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $290.00M 10-Q · filed 2026-08-05 | $398.00M derived: sum of 3 quarters · filed 2026-08-05 | $617.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $13.00M 10-Q · filed 2026-05-06 | $121.00M derived: sum of 2 quarters · filed 2026-05-06 | $340.00M derived: sum of 3 quarters · filed 2026-05-06 | $577.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $108.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $327.00M derived: sum of 2 quarters · filed 2026-02-24 | $564.00M derived: sum of 3 quarters · filed 2026-08-05 | $560.00M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $219.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $456.00M derived: sum of 2 quarters · filed 2026-08-05 | $452.00M 10-Q · filed 2025-11-05 | $629.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $237.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $233.00M 10-Q · filed 2026-08-05 | $410.00M derived: sum of 3 quarters · filed 2026-08-05 | $572.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$4.00M 10-Q · filed 2026-05-06 | $173.00M derived: sum of 2 quarters · filed 2026-05-06 | $335.00M derived: sum of 3 quarters · filed 2026-05-06 | $535.00M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $177.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $339.00M derived: sum of 2 quarters · filed 2026-02-24 | $539.00M derived: sum of 3 quarters · filed 2026-02-24 | $541.00M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $162.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $362.00M derived: sum of 2 quarters · filed 2025-11-05 | $364.00M 10-Q · filed 2025-11-05 | $521.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $200.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $202.00M 10-Q · filed 2025-08-07 | $359.00M derived: sum of 3 quarters · filed 2026-02-24 | $557.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $2.00M 10-Q · filed 2025-05-07 | $159.00M derived: sum of 2 quarters · filed 2026-02-24 | $357.00M derived: sum of 3 quarters · filed 2026-02-24 | $418.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $157.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $355.00M derived: sum of 2 quarters · filed 2026-02-24 | $416.00M derived: sum of 3 quarters · filed 2026-02-24 | $271.00M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $198.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $259.00M derived: sum of 2 quarters · filed 2024-11-07 | $114.00M 10-Q · filed 2024-11-07 | $127.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $61.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$84.00M 10-Q · filed 2024-08-08 | -$71.00M derived: sum of 3 quarters · filed 2025-02-25 | $118.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | -$145.00M 10-Q · filed 2024-05-08 | -$132.00M derived: sum of 2 quarters · filed 2025-02-25 | $57.00M derived: sum of 3 quarters · filed 2025-02-25 | $369.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $202.00M derived: sum of 2 quarters · filed 2025-02-25 | $514.00M derived: sum of 3 quarters · filed 2025-02-25 | $452.00M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $189.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $501.00M derived: sum of 2 quarters · filed 2023-11-07 | $439.00M 10-Q · filed 2023-11-07 | $662.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $312.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $250.00M 10-Q · filed 2023-08-07 | $473.00M derived: sum of 3 quarters · filed 2024-02-26 | $562.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | -$62.00M 10-Q · filed 2023-05-09 | $161.00M derived: sum of 2 quarters · filed 2024-02-26 | $250.00M derived: sum of 3 quarters · filed 2024-02-26 | $399.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $223.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $312.00M derived: sum of 2 quarters · filed 2024-02-26 | $461.00M derived: sum of 3 quarters · filed 2024-02-26 | $483.00M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $89.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $238.00M derived: sum of 2 quarters · filed 2022-11-08 | $260.00M 10-Q · filed 2022-11-08 | $167.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $149.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $171.00M 10-Q · filed 2022-08-08 | $78.00M derived: sum of 3 quarters · filed 2023-03-01 | -$34.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $22.00M 10-Q · filed 2022-05-09 | -$71.00M derived: sum of 2 quarters · filed 2023-03-01 | -$183.00M derived: sum of 3 quarters · filed 2023-03-01 | -$23.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | -$93.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$205.00M derived: sum of 2 quarters · filed 2023-03-01 | -$45.00M derived: sum of 3 quarters · filed 2023-03-01 | -$41.00M 10-K · filed 2023-03-01 | ||||
| 2020-09-30 | -$112.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $48.00M derived: sum of 2 quarters · filed 2021-11-05 | $52.00M 10-Q · filed 2021-11-05 | $51.90M 10-Q · filed 2020-11-06 | $178.20M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | $160.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $164.00M 10-Q · filed 2021-08-09 | $163.60M 10-Q · filed 2020-07-30 | $290.20M derived: sum of 3 quarters · filed 2022-02-28 | $329.80M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | $4.00M 10-Q · filed 2021-05-07 | $4.30M 10-Q · filed 2020-05-07 | $130.20M derived: sum of 2 quarters · filed 2022-02-28 | $169.80M derived: sum of 3 quarters · filed 2022-02-28 | $219.90M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $126.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $165.80M derived: sum of 2 quarters · filed 2022-02-28 | $215.90M derived: sum of 3 quarters · filed 2022-02-28 | $224.00M 10-K · filed 2022-02-28 | $224.10M 10-K · filed 2020-02-28 | |||
| 2019-09-30 | $39.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $89.70M derived: sum of 2 quarters · filed 2020-11-06 | $97.80M 10-Q · filed 2020-11-06 | $237.30M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $50.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $58.20M 10-Q · filed 2020-07-30 | $197.70M derived: sum of 3 quarters · filed 2021-03-01 | $361.60M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $8.10M 10-Q · filed 2020-05-07 | $5.60M 10-Q · filed 2019-05-14 | $147.60M derived: sum of 2 quarters · filed 2021-03-01 | $311.50M derived: sum of 3 quarters · filed 2021-03-01 | $448.40M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2018-12-31 | $139.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $303.40M derived: sum of 2 quarters · filed 2021-03-01 | $440.30M derived: sum of 3 quarters · filed 2021-03-01 | $487.30M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $163.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $300.80M derived: sum of 2 quarters · filed 2019-11-08 | $347.80M 10-Q · filed 2019-11-08 | $354.50M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-06-30 | $136.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $183.90M 10-Q · filed 2019-08-13 | $190.60M derived: sum of 3 quarters · filed 2020-02-28 | |||||
| 2018-03-31 | $47.00M 10-Q · filed 2019-05-14 | $53.70M derived: sum of 2 quarters · filed 2020-02-28 | ||||||
| 2017-12-31 | $6.70M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $173.80M 10-K · filed 2020-02-28 | ||||||
| 2017-09-30 | $167.10M 10-Q · filed 2018-11-08 | |||||||
| 2016-12-31 | $155.90M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |